Management of myocardial injury After NoncArdiac surGEry Trial
A large, international, randomized, placebo-controlled trial to assess the impact of dabigatran (a direct thrombin inhibitor) and omeprazole (a proton-pump inhibitor) in patients suffering a myocardial injury after noncardiac surgery.
Myocardial injury after noncardiac surgery (MINS) represents a major public health issue. There are no known efficacious therapies to manage patients suffering MINS. Dabigatran holds great promise as an antithrombotic agent that can potentially save lives and prevent major thrombotic events after MINS. Omeprazole also holds great promise as a proton pump inhibitor that can potentially prevent major upper gastrointestinal complications. This large trial will answer two crucial management questions for patients suffering a myocardial infarction after noncardiac surgery, and will influence future perioperative practices around the world.
Study Design: Randomized, Blinded, Placebo Control, Factorial Assignment.
Intervention: Dabigatran vs. matching placebo, omeprazole vs. matching placebo.
Length of Study: 2 year recruitment period, minimum 6 months follow-up period.
# of Patients: 3200
Patient Populations: Patients suffering myocardial injury after noncardiac surgery (MINS)
Available upon study completion.
Main Publications (A full listing of PHRI publications can be found in the 'Media & Publications' section)